A Phase II Study of Amplimexon (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Imexon (Primary)
- Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 11 Jul 2014 Status changed from active, no longer recruiting to completed according to results published in the Blood.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 18 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History